Genetic control of wayward pluripotent stem cells and their progeny after transplantation.
The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.
Kiuru
Maija
M
Department of Genetic Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
Boyer
Julie L
JL
O'Connor
Timothy P
TP
Crystal
Ronald G
RG